Larimar Therapeutics, Inc. (LRMR), Monday announced encouraging data from the ongoing long-term open label or OL study, evaluating daily subcutaneous injections of nomlabofusp in participants with Friedreich's ataxia, a rare, progressive, and systemic disease with neurologic deterioration. During the study, participants were initially administered 25 mg of nomlabofusp daily. Later, the dose was increased to 50 mg in the fourth quarter of 2024. The data showed that nomlabofusp increases skin frataxin or FXN ...